Skip to main content

Tioconazole (Monograph)

Brand names: 1-Day, Vagistat-1
Drug class: Azoles
ATC class: D01AC07
VA class: GU300
Chemical name: 1-[2-[(2-Chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
Molecular formula: C16H13Cl3N2OS
CAS number: 65899-73-2

Introduction

Antifungal; azole (imidazole derivative).2 3 49 65

Uses for Tioconazole

Vulvovaginal Candidiasis

Treatment of uncomplicated vulvovaginal candidiasis (mild to moderate, sporadic or infrequent, most likely caused by Candida albicans, occurring in immunocompetent women).1 2 108 127 128 A drug of choice.4 30 74 75 76 92 93 104 108 127 128

Self-medication (OTC use) for treatment of uncomplicated vulvovaginal candidiasis in otherwise healthy, nonpregnant women who have been previously diagnosed by a clinician and are having recurrence of similar symptoms.1 108 123 124

Treatment of complicated vulvovaginal candidiasis, including infections that are recurrent (≥4 episodes in 1 year), severe (extensive vulvar erythema, edema, excoriation, fissure formation), caused by Candida other than C. albicans, or occurring in women with underlying medical conditions (uncontrolled diabetes mellitus, HIV infection, immunosuppressive therapy, pregnancy).108 127 128 Complicated infections generally require more prolonged treatment than uncomplicated infections.108 126 127 128

Optimal regimens for treatment of vulvovaginal candidiasis caused by Candida other than C. albicans (e.g., C. glabrata, C. krusei) not identified.108 128 CDC and others state these infections may respond to an intravaginal azole antifungal given for 7–14 days or to a 14-day regimen of intravaginal boric acid (not commercially available in the US).108 128 129

Tioconazole Dosage and Administration

Administration

Intravaginal Topical Administration

Administer intravaginally as a 6.5% ointment using the prefilled applicator provided by the manufacturer.1 108 123 124

Vaginal ointment is for intravaginal administration only; do not administer orally.1 Avoid contact with the eyes.1

Administer dose intravaginally high in the vaginal vault at bedtime.1 123 124

Open applicator just prior to administration to prevent contamination.1 123 124

Dosage

Pediatric Patients

Uncomplicated Vulvovaginal Candidiasis
Intravaginal

Children ≥12 years of age: One applicatorful of 6.5% ointment (approximately 300 mg of tioconazole) as a single dose at bedtime.1 123 124 May be used for self-medication.1 123 124

If clinical symptoms do not improve within 3 days, persist for >7 days, or recur within 2 months, discontinue self-medication and consult a clinician.1 108 123 124 Confirm diagnosis and rule out other pathogens and conditions that may predispose a patient to recurrent vaginal fungal infections.1 108

HIV-infected Adolescents
Intravaginal

Use same regimen recommended for other patients.108 126 Some experts recommend a duration of 3–7 days.126 Maintenance regimen of an intravaginal azole can be considered for those with recurrent episodes;126 routine primary or secondary prophylaxis (long-term suppressive or chronic maintenance therapy) not recommended.126 108

Complicated Vulvovaginal Candidiasis
Recurrent Vulvovaginal Infections Caused by Candida albicans
Intravaginal

Adolescents: CDC and others recommend an initial intensive regimen (7–14 days of an intravaginal azole or 3-dose regimen of oral fluconazole) to achieve mycologic remission, followed by an appropriate maintenance regimen (6-month regimen of once-weekly oral fluconazole or, alternatively, an intravaginal azole given intermittently).108 127 128

Other Complicated Vulvovaginal Infections
Intravaginal

Adolescents: CDC and others recommend 7–14 days of an intravaginal azole for vulvovaginal candidiasis that is severe, caused by Candida other than C. albicans, or occurring in those with underlying medical conditions.108 127

Adults

Uncomplicated Vulvovaginal Candidiasis
Intravaginal

One applicatorful of 6.5% ointment (approximately 300 mg of tioconazole) as a single dose at bedtime.1 123 124 May be used for self-medication.1 123 124

If clinical symptoms do not improve within 3 days, persist for >7 days, or recur within 2 months, discontinue self-medication and consult a clinician.1 108 123 124 Confirm diagnosis and rule out other pathogens and conditions that may predispose a patient to recurrent vaginal fungal infections.1 108

HIV-infected Adults
Intravaginal

Use same regimen recommended for other patients.108 126 Some experts recommend a duration of 3–7 days.126 Maintenance regimen of an intravaginal azole can be considered for those with recurrent episodes;126 routine primary or secondary prophylaxis (long-term suppressive or chronic maintenance therapy) not recommended.108 126

Complicated Vulvovaginal Candidiasis
Recurrent Vulvovaginal Infections Caused by Candida albicans
Intravaginal

CDC and others recommend an initial intensive regimen (7–14 days of an intravaginal azole or 3-dose regimen of oral fluconazole) to achieve mycologic remission, followed by an appropriate maintenance regimen (6-month regimen of once-weekly oral fluconazole or, alternatively, an intravaginal azole given intermittently).108 127 128

Other Complicated Vulvovaginal Infections
Intravaginal

CDC and others recommend 7–14 days of an intravaginal azole for vulvovaginal candidiasis that is severe, caused by Candida other than C. albicans, or occurring in women with underlying medical conditions.108 127

Special Populations

Hepatic Impairment

No specific dosage recommendations at this time.a

Renal Impairment

No specific dosage recommendations at this time.a

Geriatric Patients

No specific dosage recommendations at this time.a

Detailed Tioconazole topical dosage information

Cautions for Tioconazole

Contraindications

Known hypersensitivity to tioconazole, other imidazoles, or any ingredient in the formulation.1 117

Warnings/Precautions

Warnings

Use of Latex or Rubber Products

Tioconazole vaginal ointment contains petroleum base that can weaken latex or rubber products (including condoms and vaginal contraceptive diaphragms).1 108 Use of such products within 72 hours following intravaginal tioconazole treatment not recommended.1 108 124

Sensitivity Reactions

Hypersensitivity Reactions

Contact dermatitis reported following topical application of tioconazole45 46 47 48 50 51 100 or other imidazole-derivative azole antifungals.47 49 113 114

Possible cross-sensitization among the imidazoles.45 46 47 48 49 50 51 100 113

General Precautions

Selection and Use of Antifungals for Vulvovaginal Candidiasis

Prior to initial use in a woman with signs and symptoms of vulvovaginal candidiasis, confirm diagnosis by direct microscopic examination of vaginal discharge (saline or potassium hydroxide [KOH] wet mount or Gram stain) and/or cultures.1 2 108

Candida identified by culture in the absence of symptoms is not an indication for antifungal treatment since approximately 10–20% of women harbor Candida or other yeasts in the vagina.108

If clinical symptoms persist after treatment, repeat tests to rule out other pathogens, confirm the original diagnosis, and rule out other conditions that may predispose a patient to recurrent vaginal fungal infections (e.g., HIV infection).1 2

Do not use for self-medication in women who are or think they may be pregnant or in those with diabetes mellitus, HIV infection, or HIV exposure.1 123 124

Specific Populations

Pregnancy

Category C.1

Lactation

Not known whether tioconazole is distributed into milk after intravaginal administration; temporarily discontinue nursing during treatment.1 2 117

Pediatric Use

Safety and efficacy not established in children <12 years of age.1 123 124

Common Adverse Effects

Vulvovaginal burning,1 2 10 86 123 irritation,10 123 vaginitis,1 pruritus,1 2 10 86 123 headache.1

Drug Interactions

Weak inducer of CYP450 isoenzymes.61 63

Drugs Metabolized by Hepatic Microsomal Enzymes

Potential pharmacokinetic interaction with drugs metabolized by CYP450 isoenzymes;61 63 interaction unlikely with usual single-dose intravaginal tioconazole regimen117 since only low amounts of the drug absorbed systemically.1 2

Specific Drugs

Drug

Interaction

Comments

Oral contraceptives

Efficacy of intravaginal tioconazole not affected by concomitant oral contraceptives1

Tioconazole Pharmacokinetics

Absorption

Bioavailability

Following intravaginal administration, only small amounts absorbed systemically;1 2 3 18 84 peak plasma concentrations usually attained within 2–24 hours.84

Distribution

Extent

Unabsorbed drug persists in vaginal fluid for 24–72 hours following an intravaginal dose.2 18 84 87

Not known whether tioconazole is distributed into milk.1

Elimination

Elimination Route

Does not appear to be metabolized in vaginal fluid.2 After oral administration of radiolabeled tioconazole, systemically absorbed drug excreted in urine as metabolites (25–27% of the oral dose) and in feces as unchanged drug (59% of the oral dose).2 6

Stability

Storage

Intravaginal

Ointment

15–30°C;1 123 124 expires 3 years following the date of manufacture.91

Actions and Spectrum

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Tioconazole

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Vaginal

Ointment

6.5%*

1-Day (available in prefilled, disposable applicators)

Personal Products

Tioconazole Vaginal Ointment (available in prefilled, disposable applicators)

Perrigo

Vagistat-1 (available in prefilled, disposable applicators)

Novartis

AHFS DI Essentials™. © Copyright 2025, Selected Revisions August 1, 2007. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

References

1. Bristol-Myers Squibb. Vagistat-1 (tioconazole) 6.5% vaginal ointment prescribing information. In: Physicians’ desk reference. 52nd ed. Montvale, NJ: Medical Economics Company Inc; 1998:778.

2. Mead Johnson Laboratories. Vagistat-1 (tioconazole) 6.5% one-dose vaginal ointment product monograph. Princeton, NJ; 1992.

3. Clissold SP, Heel RC. Tioconazole: a review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs. 1986; 31:29-51. https://pubmed.ncbi.nlm.nih.gov/3510114

4. Anon. Drugs for vulvovaginal candidiasis. Med Lett Drugs Ther. 2001; 43:3-4. https://pubmed.ncbi.nlm.nih.gov/11151090

5. Adetoro OO. Tioconazole in the management of recurrent vaginal candidosis during pregnancy in Ilorin, Nigeria. Curr Ther Res. 1987; 41:657-50.

6. Macrae PV, Kinns M, Pullen FS et al. Characterization of a quaternary, N- glucuronide metabolite of the imidazole antifungal, tioconazole. Drug Met Disp. 1990; 18:1100-2.

7. Beggs WH, Polman DM. Fungicidal and fungistatic actions of tioconazole. Curr Ther Res. 1985; 38:778-84.

8. Beggs WH. Lethal potential of tioconazole in relation to growth phase of Candida albicans. Curr Ther Res. 1986; 39:564-7.

9. Obasi OE, Adeleke D. Tioconazole powder in athlete’s foot. Curr Ther Res. 1987; 41:871-3.

10. Stein GE, Gurwith D, Mummaw N et al. Single-dose tioconazole compared with 3-day clotrimazole treatment in vulvovaginal candidiasis. Antimicrob Agents Chemother. 1986; 29:969-71. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC180485/ https://pubmed.ncbi.nlm.nih.gov/3524439

11. Uyanwah PO. An open non-comparative evaluation of single-dose tioconazole (6%) vaginal ointment in vaginal candidosis. Curr Ther Res. 1986; 39:30-3.

12. Haller I. Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985; 152:939-44. https://pubmed.ncbi.nlm.nih.gov/3895959

13. Somorin AO. Clinical evaluation of tioconazole in dermatophyte infections. Curr Ther Res. 1985; 37:1058-61.

14. Egere JU. An assessment of the efficacy of tioconazole in the treatment of superficial fungal infections in Jos, Nigeria. Curr Ther Res. 1986; 39:34-8.

15. Obasi OE. The treatment of superficial dermatophyte infections with tioconazole in Kaduna, Nigeria. Curr Ther Res. 1985; 37:1062-71.

16. Okafor E, Osunkwo IC, Okoro AN. Tioconazole in dermatophyte infections. Curr Ther Res. 1985; 37:1054-7.

17. Itam IH. Tioconazole in vaginal candidiasis: an open evaluation of two formulations in St. Margaret Maternity Hospital, Calabar. Curr Ther Res. 1985; 37:1048-53.

18. Houang ET, Lawrence AG. Systemic absorption and persistence of tioconazole in vaginal fluid after insertion of a single 300-mg tioconazole ovule. Antimicrob Agents Chemother. 1985; 27:964-5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC180197/ https://pubmed.ncbi.nlm.nih.gov/4026270

19. Fleury F, Hughes D, Floyd R. Therapeutic results obtained in vaginal mycoses after single-dose treatment with 500 mg clotrimazole vaginal tablets. Am J Obstet Gynecol. 1985; 152:968-70. https://pubmed.ncbi.nlm.nih.gov/3895963

20. Lebherz T, Guess E, Wolfson N. Efficacy of single- versus multiple-dose clotrimazole therapy in the management of vulvovaginal candidiasis. Am J Obstet Gynecol. 1985; 152:965-8. https://pubmed.ncbi.nlm.nih.gov/3895962

21. Akuse JT. Assessment of the efficacy of tioconazole (Trosyd) 300 mg ovules in vaginal candidosis: single-dose therapy. Curr Ther Res. 1984; 36:409-13.

22. Carmona O, Pino T, González I. Evaluation of tioconazole in the treatment of vaginal trichomoniasis. Curr Ther Res. 1985; 38:474-80.

23. Jevons S, Gymer GE, Brammer KW et al. Antifungal activity of tioconazole (UK- 20,349), a new imidazole derivative. Antimicrob Agents Chemother. 1979; 15:597-602. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC352717/ https://pubmed.ncbi.nlm.nih.gov/464592

24. Bergan T, Vangdal M. In vitro activity of antifungal agents against yeast species. Chemotherapy. 1983; 29:104-10. https://pubmed.ncbi.nlm.nih.gov/6301773

25. Lefler E, Stevens DA. Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use. Antimicrob Agents Chemother. 1984; 25:450-4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC185550/ https://pubmed.ncbi.nlm.nih.gov/6375555

26. Khan HMD, Ahmed M, Islam N et al. New 1-substituted imidazole—tioconazole—in the treatment of superficial dermal mycoses. Curr Ther Res. 1984; 35:768-71.

27. Alabi GO. Clinical trial of tioconazole (Trosyd) in dermatophyte infection in Ibadan, Nigeria. Curr Ther Res. 1985; 37:254-8.

28. Hay RJ. Recent advances in the management of fungal infections. Q J Med. 1987; 64:631-9. https://pubmed.ncbi.nlm.nih.gov/3328211

29. Sobel JD, Schmitt C, Meriwether C. Clotrimazole treatment of recurrent chronic candida vulvovaginitis. Obstet Gynecol. 1989; 73:330-4. https://pubmed.ncbi.nlm.nih.gov/2644595

30. Hay RJ. Yeast infections. Dermatol Clin. 1996; 14:113-24. https://pubmed.ncbi.nlm.nih.gov/8821164

31. Johnson EM, Richardson MD, Warnock DW. In-vitro resistance to imidazole antifungals in Candida albicans. J Antimicrob Chemother. 1984; 13:547-58. https://pubmed.ncbi.nlm.nih.gov/6381460

32. Odds FC, Abbott AB. Relative inhibition factors—a novel approach to the assessment of antifungal antibiotics in vitro. J Antimicrob Chemother. 1984; 13:31-43. https://pubmed.ncbi.nlm.nih.gov/6698909

33. Scott EM, Gorman SP, Wright LR. The effect of imidazoles on germination of arthrospores and microconidia of trichophyton mentagrophytes. J Antimicrob Chemother. 1984; 13:101-110. https://pubmed.ncbi.nlm.nih.gov/6323373

34. Odds FC, Webster CE, Abbott AB. Antifungal relative inhibition factors: BAY 1-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. J Antimicrob Chemother. 1984; 14:105-114. https://pubmed.ncbi.nlm.nih.gov/6094418

35. Johnson EM, Richardson MD, Warnock DW. Effect of imidazole antifungals on the development of germ tubes by strains of Candida albicans. J Antimicrob Chemother. 1983; 12:303-316. https://pubmed.ncbi.nlm.nih.gov/6315670

36. Latrille F, Charuel C, Stadler J et al. The effect of luteinizing hormone on parturition in rats: imidazole antifungals may affect parturition via luteinizing hormone. Res Comm Chem Pathol Pharmacol. 1988; 62:141-4.

37. Anséhn S, Nilsson L. Direct membrane-damaging effect of ketoconazole and tioconazole on Candida albicans demonstrated by bioluminescent assay of ATP. Antimicrob Agents Chemother. 1984; 26:22-5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC179909/ https://pubmed.ncbi.nlm.nih.gov/6089651

38. Odds FC, Cheesman SL, Abbott AB. Suppression of ATP in Candida albicans by imidazole and derivative antifungal agents. Sabouraudia. 1985; 23:415-24. https://pubmed.ncbi.nlm.nih.gov/3913012

39. Beggs WH. Fungicidal activity of tioconazole in relation to growth phase of Candida albicans and candida parapsilosis. Antimicrob Agents Chemother. 1984; 26:669-701.

40. Hay RJ, Clayton YM, Moore MK. A comparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clin Exp Dermatol. 1985; 12:175-7.

41. Clayton YM, Hay RJ, McGibbon DH et al. Double blind comparison of the efficacy of tioconazole and miconazole for the treatment of fungal infection of the skin or erythrasma. Clin Exp Dermatol. 1982; 7:543-51. https://pubmed.ncbi.nlm.nih.gov/6756715

42. Vander Ploeg DE, De Villez RL. A new topical antifungal drug: tioconazole. Int J Dermatol. 1984; 23:681-3. https://pubmed.ncbi.nlm.nih.gov/6396247

43. Fredriksson T. Treatment of dermatomycoses with topical tioconazole and miconazole. Dermatologica. 1983; 166(Suppl 1):14-9. https://pubmed.ncbi.nlm.nih.gov/6350071

44. Grigoriu D, Grigoriu A. Double-blind comparison of the efficacy, toleration and safety of tioconazole base 1% and econazole nitrate 1% creams in the treatment of patients with fungal infections of the skin or erythrasma. Dermatologica. 1983; 166(Suppl 1):8-13. https://pubmed.ncbi.nlm.nih.gov/6350072

45. Jones SK, Kennedy CTC. Contact dermatitis from tioconazole. Contact Dermatitis. 1990; 22:122-3. https://pubmed.ncbi.nlm.nih.gov/2138969

46. Onayemi O, Aldridge RD, Shaw S. Allergic contact dermatitis from tioconazole. Contact Dermatitis. 1992; 26:193-4. https://pubmed.ncbi.nlm.nih.gov/1387058

47. Stubb S, Heikkilä H, Reitamo S et al. Contact allergy to tioconazole. Contact Dermatitis. 1992; 26:155-8. https://pubmed.ncbi.nlm.nih.gov/1387056

48. Izu R, Aguirre A, González M et al. Contact dermatitis from tioconazole with cross- sensitivity to other imidazoles. Contact Dermatitis. 1992; 26:130-1. https://pubmed.ncbi.nlm.nih.gov/1386008

49. Baes H. Contact sensitivity to miconazole with ortho-chloro cross-sensitivity to other imidazoles. Contact Dermatitis. 1991; 24:89-93. https://pubmed.ncbi.nlm.nih.gov/1828223

50. Brunelli D, Vincenzi C, Morelli R et al. Contact dermatitis from tioconazole. Contact Dermatitis. 1992; 27:120. https://pubmed.ncbi.nlm.nih.gov/1395619

51. Marren P, Powell S. Contact sensitivity to tioconazole and other imidazoles. Contact Dermatitis. 1992; 27:129-30. https://pubmed.ncbi.nlm.nih.gov/1395626

52. Von Recklinghausen G, Di Maio C, Ansorg R. Activity of antibiotics and azole antimycotics against Helicobacter pylori. Zbl Bakt. 1993; 280:279-85.

53. Cabanes FJ, Abarca L, Bragulat M et al. Sensitivity of some strains of the genus epidermophyton to different antifungal agents. Mycopathologia. 1989; 105:153-6. https://pubmed.ncbi.nlm.nih.gov/2788246

54. Stein GE, Christensen S, Mummaw N. Comparative study of fluconazole and clotrimazole in the treatment of vulvovaginal candidiasis. DICP. 1991; 25:582-5. https://pubmed.ncbi.nlm.nih.gov/1877264

55. O’Neill East M, Henderson JT, Jevons S. Tioconazole in the treatment of fungal infections of the skin. Dermatologica. 1983; 166(Suppl 1):20-33. https://pubmed.ncbi.nlm.nih.gov/6884560

56. Rohde-Werner MH. Topical tioconazole versus systemic ketoconazole treatment of vaginal candidiasis. J Int Med Res. 1984; 12:298-302. https://pubmed.ncbi.nlm.nih.gov/6094282

57. Cohen L. Is more than one application of an antifungal necessary in the treatment of acute vaginal candidiasis? Am J Obstet Gynecol. 1985; 152:961-4. (IDIS 203429)

58. Gibbs DL, Kashin P, Jevons S. Comparative and non-comparative studies of the efficacy and tolerance of tioconazole cream 1% versus another imidazole and/or placebo in neonates and infants with candidal diaper rash and/or impetigo. J Int Med Res. 1987; 15:23-31. https://pubmed.ncbi.nlm.nih.gov/3817280

59. Nicholas RO, Kerridge D. Correlation of inhibition of sterol synthesis with growth- inhibitory action of imidazole antimycotics in Candida albicans. J Antimicrob Chemother. 1989; 23:7-19. https://pubmed.ncbi.nlm.nih.gov/2663807

60. Beggs WH. Rapid fungicidal action of tioconazole and miconazole. Mycopathologia. 1987; 97:187-8. https://pubmed.ncbi.nlm.nih.gov/3553955

61. Ritter JK, Franklin MR. Induction of hepatic oxidative and conjugative drug metabolism in the hamster by N-substituted imidazoles. Toxicol Lett. 1987; 36:51-9. https://pubmed.ncbi.nlm.nih.gov/3564069

62. Pye GW, Marriott MS. Inhibition of sterol C14 demethylation by imidazole-containing antifungals. Sabouraudia. 1982; 20:325-9. https://pubmed.ncbi.nlm.nih.gov/6760419

63. Ritter JK, Franklin MR. Induction and inhibition of rat hepatic drug metabolism by N-substituted imidazole drugs. Drug Metabol Disp. 1987; 15:335-43.

64. Marriott MS, Baird JRC, Brammer KW et al. Tioconazole, a new imidazole-antifungal agent for the treatment of dermatomycoses: antifungal and pharmacologic properties. Dermatologica. 1983; 166(Suppl 1):1-7. https://pubmed.ncbi.nlm.nih.gov/6884559

65. Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev. 1988; 1:187-217. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC358042/ https://pubmed.ncbi.nlm.nih.gov/3069196

66. Donadio C. Tioconazole 2% cream in the treatment of Trichomonas vaginalis or mixed vaginal infections. J Int Med Res. 1986; 14:50-2. https://pubmed.ncbi.nlm.nih.gov/3485546

67. Odds FC, Cockayne A, Hayward J et al. Effects of imidazole- and triazole-derivative antifungal compounds on the growth and morphological development of Candida albicans hyphae. J Gen Microbiol. 1985; 131:2581-9. https://pubmed.ncbi.nlm.nih.gov/2999296

68. Sud IJ, Feingold DS. Heterogeneity of action mechanisms among antimycotic imidazoles. Antimicrob Agents Chemother. 1981; 20:71-4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC181635/ https://pubmed.ncbi.nlm.nih.gov/6269485

69. Marriott MS. Inhibition of sterol biosynthesis in Candida albicans by imidazole- containing antifungals. J Gen Microbiol. 1980; 117:253-5. https://pubmed.ncbi.nlm.nih.gov/6993625

70. Davies AR, Marriott MS. Inhibitory effects of imidazole antifungals on the yeast- mycelial transformation in Candida albicans. Microbios Lett. 1981; 17:155-8.

71. Hänel H, Raether W, Dittmar W. Evaluation of fungicidal action in vitro and in a skin model considering the influence of penetration kinetics of various standard antimycotics. Ann N Y Acad Sci. 1988; 544:329-37. https://pubmed.ncbi.nlm.nih.gov/3214073

72. American Pharmaceutical Association. Handbook of nonprescription drugs. 10th ed. Washington, DC: American Pharmaceutical Association; 1993:503-10.

73. Ritter W, Patzschke K, Krause U et al. Pharmacokinetic fundamentals of vaginal treatment with clotrimazole. Chemotherapy. 1982; 28(Suppl 1):37-42. https://pubmed.ncbi.nlm.nih.gov/7160239

74. Doering PL, Santiago TM. Drugs for the treatment of vulvovaginal candidiasis: comparative efficacy of agents and regimens. DICP. 1990; 24:1078- 83. https://pubmed.ncbi.nlm.nih.gov/2275233

75. Sobel JD. Vaginitis. N Engl J Med. 1997; 337:1896-903. https://pubmed.ncbi.nlm.nih.gov/9407158

76. Sobel JD, Faro S, Force RW et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998; 178:203-11. https://pubmed.ncbi.nlm.nih.gov/9500475

77. Plempel M. Pharmacokinetics of imidazole antimycotics. Postgrad Med J. 1979; 55:662-6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2425660/ https://pubmed.ncbi.nlm.nih.gov/523357

78. Hughes D, Kriedman T, Hodgson C. Treatment of vulvovaginal candidiasis with a single 500-mg clotrimazole vaginal tablet compared with two 100-mg tablets daily for three days. Curr Ther Res. 1986; 39:773-7.

79. Bisschop MPJM, Merkus JMWM, Scheygrond H et al. Co-treatment of the male partner in vaginal candidosis: a double-blind randomized control study. Br J Obstet Gynecol. 1986; 93:79-81.

80. Hay RJ, Mackie RM, Clayton YM. Tioconazole nail solution—an open study of its efficacy in onychomycosis. Clin Exp Dermatol. 1985; 10:111-5. https://pubmed.ncbi.nlm.nih.gov/3156698

81. Kerridge D. Mode of action of clinically important antifungal drugs. Adv Microb Physiol. 1986; 27:38-72.

82. Odds FC, MacDonald F. Persistence of miconazole in vaginal secretions after single applications: implications for the treatment of vaginal candidosis. Br J Vener Dis. 1981; 57:400-1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1045984/ https://pubmed.ncbi.nlm.nih.gov/7326555

83. Marriott MS, Brammer KW, Faccini J et al. Tioconazole, a new broad-spectrum antifungal agent: preclinical studies related to vaginal candidiasis. Gynäk Rdsch. 1983; 23(Suppl 1):1-11.

84. Artner J, Fuchs G. Open studies of the efficacy, tolerance, systemic absorption and vaginal persistence following a single application of tioconazole ointment in the treatment of patients with vaginal candidiasis. Gynäk Rdsch. 1983; 23(Suppl 1):12-9.

85. Yoffe CA, Katz EA. Short-term treatment of Trichomonas vaginalis with tioconazole cream, a new antifungal agent. Gynäk Rdsch. 1983; 23(Suppl 1):37-41.

86. Henderson JT, Neilson W, Wilson AB et al. Tioconazole in the treatment of vaginal candidiasis: an international clinical research program. Gynäk Rdsch. 1983; 23(Suppl 1):42-60.

87. Jones RN, Bale MJ, Hoban D et al. In vitro antimicrobial activity of tioconazole and its concentrations in vaginal fluids following topical (Vagistat-1 6.5%) application. Diagn Microbiol Infect Dis. 1993; 17:45-51. https://pubmed.ncbi.nlm.nih.gov/8359005

88. Smith EB, Becker LE, Tschen EH et al. Topical tioconazole in tinea pedis. Adv Ther. 1988; 5:313-8.

89. Alchorne MMA, Paschoalick RC, Forjaz MHH. Comparative study of tioconazole and clotrimazole in the treatment of tinea versicolor. Clin Ther. 1987; 9:360-7. https://pubmed.ncbi.nlm.nih.gov/3607817

90. Anon. Antifungal agents and their use in Candida infections. In: Odds FC, ed. Candida and candidosis. 2nd ed. Philadelphia: Bailliere Tindall; 1988:293-313.

91. Mead Johnson, Princeton, NJ: Personal communication.

92. Bohannon NJV. Treatment of vulvovaginal candidiasis in patients with diabetes. Diabetes Care. 1998; 21:451-6. https://pubmed.ncbi.nlm.nih.gov/9540031

93. Tobin MJ. Vulvovaginal candidiasis: topical vs. oral therapy. Am Fam Physician. 1995; 51:1715-24. https://pubmed.ncbi.nlm.nih.gov/7754931

94. Cauwenbergh GF, Degreef H, Verhoeve LS. Topical ketoconazole in dermatology: a pharmacological and clinical review. Mykosen. 1984; 27:395-401. https://pubmed.ncbi.nlm.nih.gov/6090895

95. Ortho. Monistat 3 (miconazole nitrate) 200 mg vaginal suppositories prescribing information. In: Physicians’ desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997:1903-4.

96. Ortho. Spectazole (econazole nitrate) 1% cream prescribing information (dated 1996 Jun). In: Physicians’ desk reference. 52nd ed. Montvale, NJ: Medical Economics Company Inc; 1998:1989.

97. Janssen. Nizoral (ketoconazole) tablets prescribing information (dated 1998 Jul). In: Huff BB, ed. Physicians’ desk reference. 56th ed. Montvale, NJ: Medical Economics Company Inc; 2002:1791-2.

98. Haroon TS, Tareen MI, Hafiz A. An open study of tioconazole 1% dermal cream in patients with pityriasis versicolor. J Pakistan Med Assoc. 1984; 34:361-2.

99. Denning DW, Evans EGV, Kibbler CC et al. Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology). BMJ. 1995; 311:1277-81. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2551187/ https://pubmed.ncbi.nlm.nih.gov/7496239

100. Heikkila H, Stubb S, Reitamo S. A study of 72 patients with contact allergy to tioconazole. Br J Dermatol. 1996; 134: 678-80. https://pubmed.ncbi.nlm.nih.gov/8733370

101. Arias A, Arevalo MP, Andreu A et al. Candida glabrata: in vitro susceptibility of 84 isolates to eight antifungal agents. Chemotherapy. 1996; 42: 107-11. https://pubmed.ncbi.nlm.nih.gov/8697885

102. Krieger JN. New sexually transmitted diseases treatment guidelines. J Urol. 1995; 154: 209-13.

103. Fachin AL, Maffei CMLM, Martinez-Rossi NM. In vitro susceptibility of Trichophyton rubrum to griseofulvin and tioconazole. Induction and isolation of a resistant mutant to both antimycotic drugs. Mycopathologia. 1996; 135: 141-3. https://pubmed.ncbi.nlm.nih.gov/9066154

104. Sobel JD. Controversial aspects in the management of vulvovaginal candidiasis. J Am Acad Dermatol. 1994; 31: S10-3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160974/ https://pubmed.ncbi.nlm.nih.gov/8077494

105. Spinillo A, Capuzzo E, Gulminetti R et al. Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol. 1997; 176: 138-41. https://pubmed.ncbi.nlm.nih.gov/9024104

106. Chaim W. Fungal vaginitis caused by nonalbicans species. Am J Obstet Gynecol. 1997; 177: 485. https://pubmed.ncbi.nlm.nih.gov/9290485

107. Spinillo A, Capuzzo E. Fungal vaginitis caused by nonalbicans species. Am J Obstet Gynecol. 1997; 177: 485-6.

108. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2006. MMWR Recomm Rep. 2006; 55(No. RR-11):1-85.

109. Redondo-Lopez V, Lynch M, Schmitt C et al. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet Gynecol. 1990; 76: 651-5.

110. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis. 1997; 24: 235-47. https://pubmed.ncbi.nlm.nih.gov/9114154

111. Alexander BD, Perfect JR. Antifungal resistance trends towards the year 2000: implication for therapy and new approaches. Drugs. 1997; 54: 657-678. https://pubmed.ncbi.nlm.nih.gov/9360056

112. Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis. 1992; 14(Suppl 1):S148-53.

113. Bigardi AS, Pigatto PD, Altomare G. Allergic contact dermatitis due to sulconazole. Contact Dermatitis. 1992; 26:281-2. https://pubmed.ncbi.nlm.nih.gov/1395584

114. Raulin C, Frosch PJ. Contact allergy to oxiconazole. Contact Dermatitis. 1987; 16:39-40. https://pubmed.ncbi.nlm.nih.gov/3816206

115. Westwood Squibb Pharmaceuticals, Inc. Exelderm (sulconazole nitrate) 1% cream prescribing information. In: Physicians’ desk reference. 52nd ed. Montvale, NJ: Medical Economics Company Inc; 1998:2993.

116. Sug IJ, Chou DL, Feingold DS. Effect of free fatty acids on liposome susceptibility to imidazole antifungals. Antimicrob Agents Chemother. 1979; 16:660-3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC352925/ https://pubmed.ncbi.nlm.nih.gov/393166

117. Reviewers’ comments (personal observations).

118. Anderson GM, Barrat J, Bergan T et al. A comparison of single-dose oral fluconazole with 3-day intravaginal clotrimazole in the treatment of vaginal candidiasis: report of an international multicentre trial. Br J Obstet Gynaecol. 1989; 96:226-32. https://pubmed.ncbi.nlm.nih.gov/2539186

119. Timonen H. Shorter treatment for vaginal candidosis: comparison between single- dose oral fluconazole and three-day treatment with local miconazole. Mycoses. 1992; 317-20.

120. Sunenshine PJ, Schwartz RA, Janniger CK. Tinea versicolor: an update. Cutis. 1998; 61:65-72. https://pubmed.ncbi.nlm.nih.gov/9515210

121. Assaf RR, Weil ML. The superficial mycoses. Dermatol Clin. 1996; 14:57-67. https://pubmed.ncbi.nlm.nih.gov/8821158

122. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. J Am Acad Dermatol. 1996; 34:287-9. https://pubmed.ncbi.nlm.nih.gov/8642095

123. Novartis. Vagistat-1 product information. From novartis website. Accessed 2007 May 4. http://www.novartis.com/consumerhealth/OTC/facts/pop-vagistat-1.htm

124. Personal Products Company. 1-Day (tioconazole ointment 6.5%) vaginal antifungal product information. Skillman, NJ; 2001.

125. Bristol-Myers Squibb. Vagistat-1 (tioconazole) 6.5% vaginal ointment prescribing information. In: Physicians’ desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997:783.

126. Centers for Disease Control and Prevention. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep. 2004; 53(RR-15):1-112. https://www.cdc.gov/mmwr/PDF/rr/rr5315.pdf

127. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists, number 72, May 2006: vaginitis. Obste Gynecol. 2006; 107:1195-296.

128. Pappas GP, Rex JR, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004; 38:161-89. https://pubmed.ncbi.nlm.nih.gov/14699449

129. Anon. Antifungal drugs. Treat Guidel Med Lett. 2005; 3:7-14. https://pubmed.ncbi.nlm.nih.gov/15671963

a. AHFS drug information 2007. McEvoy GK, ed. Tioconazole. Bethesda, MD: American Society of Health-System Pharmacists; 2007:3483-7.

Medical Disclaimer